FR940804-2-00091 FR940804-2-00047 [Docket No. 94N&hyph;0287] Glaxo, Inc., et al.; Withdrawal of Approval of 13 Abbreviated Antibiotic Applications and 2 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 13 abbreviated antibiotic applications (AADA's) and 2 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no being longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: September 6, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table below have informed FDA that these drug products are no longer being marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing. 1Application no. 1Drug 1Applicant AADA 61&hyph;231 Crystalline Penicillin G Potassium (bulk) Glaxo, Inc., Five Moore Dr., P.O. Box 13358, Research Triangle Park, NC 27709. AADA 61&hyph;232 Crystalline Penicillin G Sodium (bulk) Do. AADA 61&hyph;324 Penicillin G Procaine (bulk) Do. AADA 61&hyph;491 Penicillin G Procaine Type ``A'' (bulk) Do. AADA 61&hyph;705 Tetracycline Hydrochloride Tablets, U.S.P., 250 milligrams (mg) and 500 mg The Upjohn Co., 7000 Portage Rd., Kalamazoo, MI 49001. AADA 61&hyph;743 Erythromycin Stearate Tablets, U.S.P., 250 mg Purepac Pharmaceutical Co., 200 Elmora Ave., Elizabeth, NJ 07207. AADA 61&hyph;945 Sterile Penicillin G Potassium Buffered (bulk) Glaxo, Inc. AADA 629&hyph;053 Rifampin, U.S.P., (nonsterile bulk) Marion Merrill Dow, Inc., Marion Park Dr., Kansas City, MO 64134&hyph;0627. AADA 62&hyph;213 Sterile Penicillin G Sodium Buffered (bulk) Glaxo, Inc. AADA 62&hyph;297 Ampicillin for Oral Squibb, Suspension,U.S.P., 125 mg/5 milliliters (mL) and 250 mg/5 mL Bristol-Myers Co., P.O. Box 4755, Syracuse, NY 13221&hyph;4755. AADA 62&hyph;399 Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, U.S.P. Pharmafair, Inc., 110 Kennedy Dr., Hauppauge, NY 11788. AADA 62&hyph;404 Sterile Cephalothin Sodium, U.S.P. (bulk) Glaxo, Inc. AADA 62&hyph;435 Cephalothin Sodium for Injection, U.S.P. Do. ANDA 88&hyph;101 Naphazoline Hydrochloride Ophthalmic Solution, U.S.P., 0.1% Pharmafair, Inc. ANDA 88&hyph;230 Tropicamide Ophthalmic Solution, U.S.P., 1% Do. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 6, 1994. Dated: July 26, 1994. Janet Woodcock, Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;18971 Filed 8&hyph;3&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
